Speaking to Viatris CEO Michael Goettler on the first anniversary of the merger between Mylan and Upjohn, his enthusiasm for the firm’s achievements over the past 12 months is immediately obvious.
Viatris CEO Talks Integration, Roadmap And Interchangeable Biosimilars
Michael Goettler Sets Out Vision For Viatris On Anniversary Of Mylan-Upjohn Merger
As CEO Michael Goettler provides an update on the progress made by Viatris in its first year as a combined company, he also offers Generics Bulletin hints as to the detailed strategy that will be unveiled at the firm’s upcoming investor day and explains how biosimilars – including interchangeable Semglee (insulin glargine) – and complex generics are important components of the firm’s future growth plans.
More from Global Vision
More from In Vivo
• By
In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.
• By
The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
• By
Top 30 leaders: see the list of industry influencers highlighted in the sixth edition of In Vivo's Rising Leaders series.